You are here

John Knight, PhD

John Knight, PhD
Assistant Professor
Department of Urology
Phone: (205) 996-2295

John Knight received his Ph.D. in Physiology at the University of Newcastle-upon-Tyne in 2001. He completed two postdoctoral fellowships at Wake Forest University Health Sciences, and was an Assistant Professor in the Department of Urology at Wake Forest University Health Sciences until 2012.

In 2012 he joined the Department of Urology at the University of Alabama at Birmingham where he is currently an Assistant Professor. His current research interests include performing carefully controlled dietary studies in human subjects to better understand what dietary factors influence calcium oxalate kidney stone risk, and examining the role of oxalate degrading gut microbes in reducing the risk of kidney stone disease.

Selected Publications

  1. Li X, Ellis ML, Dowell AE, Kumar R, Morrow CD, Schoeb TR, Knight J. Response of germ-free mice to colonization with O. formigenes and altered Schaedler flora. Appl Environ Microbiol. 2016  Sept 26
  2. Ellis ML, Dowell AE, Li X and Knight J.  Probiotic properties of Oxalobacter formigenes: an in vitro examination. Archives of Microbiology 2016 Jul 23: p 1-8.
  3. Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol. 2016 Jul 18.
  4. Knight J, Madduma-Liyanage K, Mobley JA, Assimos DG, Holmes RP. Ascorbic acid intake and oxalate synthesis. Urolithiasis. 2016 Aug;44(4):289-97.
  5. Ellis ML, Mobley JA, Holmes RP and Knight J.  Proteome Dynamics of the specialist oxalate degrader Oxalobacter formigenes. J Proteomics & Bioinformatics  2016: 9:1
  6. Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta. 2016 Feb;1862(2):233-9
  7. Lange JN, Wood KD, Knight J, Assimos DG, Holmes RP. Glyoxal formation and its role in endogenous oxalate synthesis. Advances in Urology 2012: 2012: 19202
  8. Knight J, Holmes RP, Cramer SD, Takayama T, Salido EC. Hydroxyproline metabolism in mouse models of primary hyperoxaluria. Am J Physiol Renal Physiol 2012 Mar 15;302(6):F688-93
  9. Jiang J, Johnson LC, Knight J, Callahan MF, Holmes RP, Lowther WT. Metabolism of 13C5-hydroxyproline metabolism in vitro and in vivo: implications for primary hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G637-43
  10. Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG (2011). Impact of Dietary Calcium and Oxalate, and Oxalobacter Formigenes Colonization on Urinary Oxalate Excretion. Journal of Urology. 186(1):135-9.
  11. Knight J, Jiang J, Wood, KD, Holmes RP, Assimos DG (2011). Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers. Urology. 78(2):475.e9-475.e13
  12. Knight J, Assimos DG, Holmes RP, Callahan MF. (2010). Metabolism of Primed, Constant Infusions of [1,2-13C2] Glycine and [1-13C1] Phenylalanine to Urinary Oxalate. Metabolism: clinical and experimental. 60(7):950-6.
  13. Knight, J, Holmes RP, Assimos, DG (2007).  Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urological Research 35 (3): 111-7.
  14. Knight, J, Jiang J, Assimos DG, Holmes RP (2006).  Hydroxyproline Ingestion and urinary oxalate and glycolate excretion. Kidney international 70 (11): 1929-34